A Multi-centric, Open-label, Phase II Study Investigating the Combination of Afinitor With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced (Stage IV) Large Cell Lung Cancer With Neuroendocrine Differentiation (LC-NEC).

Trial Profile

A Multi-centric, Open-label, Phase II Study Investigating the Combination of Afinitor With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced (Stage IV) Large Cell Lung Cancer With Neuroendocrine Differentiation (LC-NEC).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 May 2017

At a glance

  • Drugs Everolimus (Primary) ; Carboplatin; Paclitaxel
  • Indications Large cell carcinoma; Lung cancer; Neuroendocrine carcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 23 May 2017 Results published in the Annals of Oncology
    • 23 May 2017 Status changed from completed to discontinued according to results published in the Annals of Oncology
    • 16 Apr 2015 Status changed from active, no longer recruiting to completed, according to to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top